Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus

The FDA has approved Merck's Enflonsia (clesrovimab), a monoclonal antibody to prevent RSV in infants, setting up competition with Sanofi and AstraZeneca's Beyfortus, which generated $1.8 billion in sales last year. Merck anticipates shipping Enflonsia before the next RSV season, citing trial data showing an 84% reduction in RSV-related hospitalizations, while Sanofi highlights Beyfortus' 75% reduction in medically attended lower respiratory infections and longer duration of protection; pricing and resistance potential may further differentiate the drugs in the market.

Analysis

The U.S. Food and Drug Administration (FDA) has approved Merck’s monoclonal antibody, Enflonsia (clesrovimab), for the prevention of RSV-induced lower respiratory tract disease in infants, positioning it as a direct competitor to Sanofi and AstraZeneca’s Beyfortus, which achieved sales of 1.7 billion euros ($1.8 billion) last year. This approval, granted ahead of the target date, allows Merck to potentially enter the market before the next RSV season, with shipments expected accordingly. Enflonsia demonstrated an 84% reduction in RSV-related hospitalizations and a 60% reduction in medically attended lower respiratory infections (MALRI) in clinical trials. Key differentiating factors for Enflonsia include a single-dose regimen and Merck's assertion of a lower propensity for viral resistance compared to Beyfortus. Conversely, Sanofi highlights Beyfortus's 75% MALRI reduction and a six-month protection window reflected on its European label. Sanofi and AstraZeneca have also confirmed increased manufacturing capacity for Beyfortus. The CDC’s Advisory Committee on Immunization Practices is set to formulate recommendations for Enflonsia's use in late June, which will be crucial for its adoption. The broader RSV market also sees competition from GSK’s Arexvy, Pfizer’s Abrysvo (which also has a maternal vaccine indication for newborns, potentially offering a cost advantage over antibodies), and Moderna’s mRESVIA for older adults. The significant market opportunity is highlighted by approximately 58,000 annual U.S. infant hospitalizations due to RSV.

Key Decisions for Investors

• Investors in Merck (MRK) should evaluate Enflonsia's market penetration strategy and initial sales figures, as its commercial success will depend on effectively challenging Beyfortus based on its single-dose administration, strong clinical data, and potential advantages regarding viral resistance.
• Sanofi (SNY) and AstraZeneca (AZN) investors should monitor for shifts in Beyfortus's market share and pricing power due to the new competitive pressure from Enflonsia, while also considering their increased production capacity and Beyfortus's established efficacy profile, including its reported higher MALRI reduction and longer protection data.
• The evolving RSV prevention market necessitates a comparative analysis across all involved companies (MRK, SNY, AZN, PFE, GSK, MRNA); institutional investors should focus on emerging differentiators such as real-world effectiveness, cost-effectiveness, adoption rates by healthcare providers, and payer reimbursement terms to identify long-term value creation.